Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.94 |
| ▸ | THRB | P10828 | 11/20 | 0.74 |
| ▸ | THRA | P10827 | 10/20 | 0.74 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
| ▸ | ASPH | Q12797 | 1/20 | 0.74 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.74 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.74 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522957 | 0.97 | EGLN1 (1.00) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL30274439 | 0.89 | EGLN1 (0.86) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL523845 | 0.89 | EGLN1 (0.86) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL16841133 | 0.89 | EGLN1 (0.88) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL522741 | 0.89 | EGLN1 (1.00) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL522900 | 0.88 | EGLN1 (1.00) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL523036 | 0.87 | EGLN1 (0.84) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL3789365 | 0.85 | THRA (0.88) | EGLN1THRBTHRABBOX1SLC6A2 | |
| Roxadustat SCHEMBL523705 | 0.85 | THRA (1.00) | EGLN1THRBTHRABBOX1SLC6A2 | |
| SCHEMBL10224811 | 0.85 | THRA (0.88) | EGLN1THRBTHRABBOX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3219706-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | Fibrogen, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219706-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | Fibrogen, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9708269-B2 | Process for making isoquinoline compounds | FIBROGEN, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708269-B2 | Process for making isoquinoline compounds | FIBROGEN, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708269-B2 | Process for making isoquinoline compounds | FIBROGEN, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2872487-B1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | FIBROGEN INC (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-2872487-B1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | FIBROGEN INC (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20160194285-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | FIBROGEN, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194285-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | FIBROGEN, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194285-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | FIBROGEN, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9340511-B2 | Process for making isoquinoline compounds | FIBROGEN, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340511-B2 | Process for making isoquinoline compounds | FIBROGEN, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340511-B2 | Process for making isoquinoline compounds | FIBROGEN, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150175550-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | FIBROGEN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175550-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | FIBROGEN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175550-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | FIBROGEN, INC. | 2015-06-25 | — | — | US | disclosed |
| EP-2872487-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | Fibrogen, Inc. (US) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014014834-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | FIBROGEN, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175550-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | HIF1AN, HIF1A, EGLN3 | EGLN1 5/4885THRB 3625/4885THRA 3768/4885 |
| US-20160194285-A1 | PROCESS FOR MAKING ISOQUINOLINE COMPOUNDS | HIF1AN, HIF1A, EGLN3 | EGLN1 5/4885THRB 3625/4885THRA 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.